Betacoronavirus

Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have Signed MoU to Advance First-of-its-Kind Infectious Disease Solutions

Retrieved on:

Thursday, October 5, 2023

Yellow fever, Partnership, Infection, Technology transfer, Dengue fever, Collaboration, Government, Kingdom, Betacoronavirus, Entrepreneurship, VIC, Marketing, MENA, GCC, Vaccine, Pharmaceutical industry, Coronavirus

This Collaboration supports the Kingdom of Saudi Arabia’s Vision 2030 to boost the biopharma sector through increasing local and regional production as well as accessibility of healthcare solutions.

Key Points:

This Collaboration supports the Kingdom of Saudi Arabia’s Vision 2030 to boost the biopharma sector through increasing local and regional production as well as accessibility of healthcare solutions.
ABINGDON, United Kingdom, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’) a clinical-stage biotechnology company on the forefront of combatting global infectious diseases, has announced that the Company has signed a Memorandum of Understanding with the Vaccine Industrial Company (VIC) for a Collaboration Agreement advancing Emergex’s novel T cell-priming immune set-point candidates against designated infectious diseases.
This agreement is a testament to Emergex’s promising technology as a vital contributor to game changing healthcare solutions around the world.
Emergex’s novel approach offers a safe, easy-to-administer and highly effective solution, alternative to mainstream methods, to protect against infectious diseases.

DIOSynVax and Ethris Publish Preclinical Proof of Concept for Their Broadly Protective Vaccine Technologies in Nature Biomedical Engineering

Retrieved on:

Monday, September 25, 2023

Vaccine, Movement, Nature Biomedical Engineering, Antigen, Therapy, SARS-CoV-2, Biotechnology, RNA, Messenger, Betacoronavirus, RaTG13, LNP, Virus

“Prior to the last pandemic, we had already experienced the serious threat of betacoronavirus outbreaks and grappled with the evolving variants that continually emerge.

Key Points:

“Prior to the last pandemic, we had already experienced the serious threat of betacoronavirus outbreaks and grappled with the evolving variants that continually emerge.
Today’s publication in collaboration with DIOSynVax serves as a strong validation and provides important preclinical evidence showcasing the efficacy of our mRNA modification and design technologies as well as our advanced stabilized nanoparticle delivery platform,” said Dr. Carsten Rudolph, CEO of Ethris.
“Through our suite of in-house developed mRNA and LNP technology platforms, we are able to create candidates with superior thermostability and resistance to mechanical manipulation.
DIOSynVax’s technology generated a panel of antigens (T2_13 to T2_17), with T2_17 proving most effective in stimulating broad immune responses to clinically relevant viruses.

Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses

Retrieved on:

Wednesday, July 19, 2023

Volunteering, University, Dengue fever, SARS-CoV-2, Lausanne, COVID-19, Infection, RNA, CHUV, University of Lausanne, Gold, Orthornavirae, Peptide, Entrepreneurship, Disease, Safety, Vaccine, Betacoronavirus

Assessment of primary outcome measures of the trial indicate that CoronaTcP showed a favourable safety profile, with no treatment-related serious adverse events observed.

Key Points:

Assessment of primary outcome measures of the trial indicate that CoronaTcP showed a favourable safety profile, with no treatment-related serious adverse events observed.
There was no systematic difference between groups that received high or low dose CoronaTcP, in terms of overall safety or reactogenicity.
In secondary immunogenicity analyses, the assessment of baseline levels of SARS-CoV-2-specific anti-nucleoprotein antibodies indicated most participants had experienced previous SARS-CoV-2 infection.
Professor Thomas Rademacher, Co-Founder and Chief Executive Officer, Emergex, said: “The positive data from both clinical trials – naNO-DENGUE and naNO-COVID - represent an important landmark for Emergex.

Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates

Retrieved on:

Tuesday, June 20, 2023

Fiocruz has a strong commercial track record in the healthcare space, with expertise in the development, manufacturing, regulatory approval, and commercialization of medicines and medical diagnostics in Brazil.

Key Points:

Fiocruz has a strong commercial track record in the healthcare space, with expertise in the development, manufacturing, regulatory approval, and commercialization of medicines and medical diagnostics in Brazil.
Both clinical trial product candidates have successfully completed Phase I+ clinical trials in Switzerland and are nearing submission and evaluation by ANVISA, the Brazilian health regulatory agency.
A Joint Steering Committee with representatives from both Emergex and IBMP will oversee the collaboration and commercialization of the select immunotherapies.
IBMP has also made an early equity investment into Emergex, which has potential for future expansion pending the completion of its ongoing due diligence process.

Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Betacoronaviruses

Retrieved on:

Wednesday, December 21, 2022

Ethris GmbH , a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilisation platforms.

Key Points:

Ethris GmbH , a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilisation platforms.
The collaboration is founded on a $42 million award to DIOSynVax by the Coalition for Epidemic Preparedness Innovations (CEPI) to support the development of a broadly protective Betacoronavirus vaccine through to a Phase I/II clinical trial.
Ethris will receive up to $20M to design and manufacture the mRNA vaccine candidate containing DIOSynVax’s broadly protective, multi-virus vaccine antigen payload designs.
The company has established its proprietary platforms to design and manufacture next-generation, well-tolerated, mRNA drug candidates with unparalleled LNP stability.

Tripledemic Leaves Consumers Scrambling for Solutions

Retrieved on:

Tuesday, December 6, 2022

MIAMI, Dec. 6, 2022 /PRNewswire/ -- As an onslaught of Respiratory Synctial Virus (RSV) and cold and flu season creates a perfect storm of illnesses over the next several months, people are wondering what they can do to stay healthy. One Miami-based physician and scientists at Tel Aviv University announced important findings from a study that shows a nutraceutical called DEFENSE can add an extra layer of protection by forming a barrier to stop viruses from entering the cells in the lungs and other areas of the body. The patented preventative respiratory support formula is an important development because it is believed to be one of the only nutraceuticals proven to reduce risk, help alleviate symptoms, and stop viruses from spreading.

Key Points:

"With experts warning of a spike in immune-resistant respiratory illnesses over the next several months, we will see people looking for solutions to stay healthy.
Fortunately, we can now say with certainty that DEFENSE is so effective at stopping viruses in their tracks that everyone should have it in their medicine cabinets."
Formulated by renowned scientists at Tel Aviv University, DEFENSE has 10 active ingredients, including Zinc, Vitamin A, Vitamin D3, Selenium, Grapefruit, Quercetin, and more.
Our unique formulation called DEFENSE is effective because it significantly enhances the performance of zinc, thereby preventing and reducing symptoms."

Avrio Health L.P. Announces Publication of In Vitro Test Results Assessing Betadine® Formulations Against Four Coronaviruses

Retrieved on:

Thursday, October 14, 2021

Avrio Health L.P. today announced the publication of results from two in vitro laboratory studies assessing Betadine antiseptic products (active ingredient: povidone-iodine or PVP-I) against four coronaviruses used as a surrogate for SARS-CoV-2.

Key Points:

Avrio Health L.P. today announced the publication of results from two in vitro laboratory studies assessing Betadine antiseptic products (active ingredient: povidone-iodine or PVP-I) against four coronaviruses used as a surrogate for SARS-CoV-2.
The studies, published in Infectious Diseases and Therapy , found that Betadine Topical Solution, Betadine Surgical Scrub, and Betadine Gargle demonstrated virucidal activity against the coronaviruses studied.
Avrio Health is committed to scientific exploration to help inform health care provider response to public health needs.
Betadine Topical Solution (containing 5.0% and 10.0% PVP-I), Betadine Surgical Scrub (containing 7.5% PVP-I), and Betadine Gargle (containing 0.5% PVP-I) were compared to placebo in two separate in vitro studies and showed virucidal activity against four coronaviruses.

Vertosa Announces U.S. Patent, Engages Emery Pharma for Research That Applies Their Pharmaceutical Development Expertise to Cannabis-Infused Products

Retrieved on:

Tuesday, July 27, 2021

Research, Tobacco, Specialty, Biotechnology, Alternative medicine, Health, Pharmaceutical, Retail, Science, Zoonoses, Sarbecovirus, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Betacoronavirus, Vertosa, Emery Pharma, VERTOSA, EMERY PHARMA

Founded in 2018, Vertosa is a science-first cannabis company that creates the most effective and reliable active ingredients for infused products.

Key Points:

Founded in 2018, Vertosa is a science-first cannabis company that creates the most effective and reliable active ingredients for infused products.
The team at Emery Pharma is skilled in Method Development and Validation, Characterization and Isolation of impurities, Stability Studies, and Release Testing.
Emery Pharma also develops methods and procedures in support of patent litigation , intellectual property, drug recalls, and product liability cases.
Since March 2020, Emery Pharma has engaged in development of a Sars-CoV-2 surrogate betacoronavirus assay for antiviral efficacy testing.

GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update

Retrieved on:

Thursday, May 6, 2021

Zoonoses, Sarbecovirus, Animal diseases, Veterinary medicine, Bat virome, Merbecovirus, Betacoronavirus, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, COVID-19

Details are provided further below.\nCapital Resources\xe2\x80\x93 On February 11, 2021, GeoVax supplemented its cash resources through a $10.3 million follow-on offering of common stock ($9.4 million net proceeds).

Key Points:

Details are provided further below.\nCapital Resources\xe2\x80\x93 On February 11, 2021, GeoVax supplemented its cash resources through a $10.3 million follow-on offering of common stock ($9.4 million net proceeds).
SARS-CoV-2 is a type of coronavirus (a Betacoronavirus) that also causes Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.
We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.\n'

Integral Molecular Expands its Reporter Virus Technology to Enable Broad Testing for Coronavirus Protection Against Emerging Strains Including D614G

Retrieved on:

Tuesday, July 14, 2020

Viruses, Zoonoses, Coronaviridae, Animal virology, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Coronavirus, Vaccine, Middle East respiratory syndrome-related coronavirus, Betacoronavirus

These variants will test the breadth of protection afforded by COVID-19 therapeutics and vaccines against newly emerging or resistant strains of the virus.

Key Points:

These variants will test the breadth of protection afforded by COVID-19 therapeutics and vaccines against newly emerging or resistant strains of the virus.
Virus neutralization testing using RVPs is being adopted by vaccine companies for screening sera from clinical trials to provide rapid and safe testing under standard BSL-2 laboratory conditions.
Viruses mutate and change over time and these mutations can compromise the efficacy of drugs or vaccines through resistance.
SARS-CoV-2 is closely related to other coronaviruses that also cause severe illnesses, including SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) virus.